Clinical experience with Hexabrix in cerebral angiography.
Sixty patients from the University of British Columbia, Vancouver General Hospital, and University of Alberta Hospitals Edmonton participated in an open-labelled clinical study on the safety, tolerability and efficacy of ioxaglic acid (Hexabrix) in cerebral angiography. Only 4% of patients experienced significant pain during carotid and brachiocephalic injections of Hexabrix. No increased incidence of side effects or adverse effects were encountered. In addition, radiographic film quality overall was excellent and comparable to that obtained using conventional contrast agents. Hexabrix is a safe and effective contrast agent for cerebral angiography.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002533:Cerebral Angiography / Q000009:adverse effects; D003287:Contrast Media / Q000009:adverse effects; D005260:Female; D006801:Humans; D007463:Iodobenzoates; D007485:Ioxaglic Acid; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D014283:Triiodobenzoic Acids / Q000009:adverse effects
D003287:Contrast Media; D007463:Iodobenzoates; D014283:Triiodobenzoic Acids; D007485:Ioxaglic Acid